Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis

Cardiol J. 2021;28(3):492-493. doi: 10.5603/CJ.a2021.0037. Epub 2021 Apr 12.
No abstract available

Publication types

  • Letter
  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Cardiotonic Agents / adverse effects
  • Dobutamine
  • Heart Failure* / diagnosis
  • Heart Failure* / drug therapy
  • Humans
  • Hydrazones
  • Pyridazines* / adverse effects
  • Simendan
  • Treatment Outcome

Substances

  • Cardiotonic Agents
  • Hydrazones
  • Pyridazines
  • Simendan
  • Dobutamine